Our recent study has demonstrated that the activation of heteromeric TRPC4 and TRPC1 (TRPC4/C1) causes a potent cytotoxic effect on SW982 cells mediated via Na+ loading [21], suggesting that heteromeric TRPC4/C1 is a promising target of anti-tumor agents against synovial sarcoma. The gene discussed is TRPC1; the disease is synovial sarcoma.